XML 82 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Restructuring and Related Charges
 3 Months Ended
Dec. 26, 2014
Restructuring and Related Activities [Abstract]  
Restructuring and Related Charges
5.
Restructuring and Related Charges
During fiscal 2013, the Company launched a restructuring program designed to improve its cost structure ("the 2013 Mallinckrodt Program"). The 2013 Mallinckrodt Program includes actions across all segments, as well as within corporate functions. The Company expects to incur charges of $100.0 million to $125.0 million under this program as the specific actions required to execute on these initiatives are identified and approved, most of which are expected to be incurred by the end of fiscal 2016. In addition to the 2013 Mallinckrodt Program, the Company has taken restructuring actions to generate synergies from its fiscal 2014 acquisitions.
Net restructuring and related charges by segment were as follows:
 
Three Months Ended
 
December 26,
2014
 
December 27,
2013
Specialty Brands
$
14.2

 
$
—

Specialty Generics
—

 
—

Global Medical Imaging
(7.3
)
 
8.1

Corporate
0.4

 
—

Restructuring and related charges, net
7.3

 
8.1

Less: accelerated depreciation
(0.1
)
 
(0.1
)
Restructuring charges, net
$
7.2

 
$
8.0



Net restructuring and related charges were comprised of the following:
 
Three Months Ended
 
December 26,
2014
 
December 27,
2013
2013 Mallinckrodt Program
$
(4.9
)
 
$
8.3

Acquisitions
12.2

 
—

Other
—

 
(0.2
)
Total
7.3

 
8.1

Less: non-cash charges, including accelerated share-based compensation expense
(6.9
)
 
(0.1
)
Total charges expected to be settled in cash
$
0.4

 
$
8.0



Non-cash charges during the three months ended December 26, 2014 included $6.8 million of accelerated share-based compensation expense related to employee terminations, primarily related to the Questcor Acquisition.
The following table summarizes cash activity for restructuring reserves, substantially all of which are related to employee severance and benefits:
 
2013 Mallinckrodt Program
 
Acquisitions
 
Other
 
Total
Balance at September 26, 2014
$
26.6

 
$
7.9

 
$
0.4

 
$
34.9

Charges
2.5

 
6.3

 
—

 
8.8

Changes in estimate
(7.5
)
 
(0.9
)
 
—

 
(8.4
)
Cash payments
(8.4
)
 
(6.3
)
 
(0.1
)
 
(14.8
)
Currency translation
(0.4
)
 
—

 
—

 
(0.4
)
Balance at December 26, 2014
$
12.8

 
$
7.0

 
$
0.3

 
$
20.1



Net restructuring and related charges, including associated asset impairments, incurred cumulative-to-date related to the 2013 Mallinckrodt Program were as follows:
Specialty Brands
$
3.0

Specialty Generics
11.5

Global Medical Imaging
64.3

Corporate
5.7

 
$
84.5



Substantially all of the restructuring reserves were included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets.